Navigation Links
Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
Date:4/12/2011

SAN DIEGO, April 12, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA.  The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February, 2011.  Jim Scopa from MPM will join the Conatus Board of Directors.

Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.

"We've watched the progress at Conatus and believe that CTS-1027 could make a significant difference in the treatment of HCV infection.  MPM also expects to provide other resources, both strategic and clinical, to assist the management team in the execution of its business plan", said Jim Scopa, Managing Director of MPM Capital.

"The additional investment by MPM enables Conatus to move ahead assertively with its confirming Phase 2b clinical trial of CTS-1027 started in January 2011 as well as allowing for a thorough evaluation of the development compounds of Idun Pharmaceuticals acquired in 2010," said Steven J. Mento, Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
2. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
3. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
10. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
11. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... SANTA CLARA, Calif. , Jan. 23, 2017 ... hand protection market, Frost & Sullivan recognizes Ansell, ... 2016 Global Frost & Sullivan Company of the ... strong customer-centric approach, and a wide global footprint ... eminence in the hand protection market. The Company,s ...
(Date:1/23/2017)... Jan. 23, 2017 MouthWatch LLC announced today that ... ranked as the best intraoral camera on DentalCompare,s list of ... spot overall. The #1 product was the CollaPlug Absorbable ... intraoral camera was "…incredibly popular because it is by far ... a small sticker price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)... Jan. 23, 2017 Direct-to-consumer ... devices sold and 65% increase in consumable sales, quarter-over-quarter ... Corp. (NASDAQ: DRIO ), a leader in ... of the Dario™ Blood Glucose Monitoring System, an all-in-one ... mobile app-based and minimally invasive smart diabetes management solution. ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: ... Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor of ... a bachelor degree in religious education and a master degree in theology. , ““The ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... on Friday, January 20, with the bipartisan original co-sponsorship of nearly one-quarter of ... January 12. The National Association of Chain Drug Stores (NACDS) strongly backs the ...
(Date:1/24/2017)... ... 23, 2017 , ... Texas Home Health, an AccentCare, Inc. ... care service companies: Padre Home Health in Corpus Christi, Texas, and Royalty Personal ... regarded in their respective markets, these two agencies align with Texas Home Health’s ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The National Council ... for drug and alcohol awareness, have worked with communities to designate the last full ... January 23-29, 2017, the theme is “Shatter the Myths.” As a community, we ...
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical Academy ... Summit to be held March 23-25, 2017 in Tampa, and reminded educators and ... The keynote speakers include Dr. Michelle R. Weise, executive director of the Sandbox ...
Breaking Medicine News(10 mins):